There are currently 1477 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778
Recruiting
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Texas Oncology - Methodist Dallas Cancer Center /ID# 269554, Dallas, Texas
Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Register for Updates
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
NCT05219617
Recruiting
The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in pediatric and adult subjects (age 4-55 years) diagnosed with Lennox Gastaut Syndrome (LGS).
Gender:
ALL
Ages:
Between 4 years and 55 years
Trial Updated:
07/21/2025
Locations: Neurology Consultants of Dallas, PA - Hospital, Dallas, Texas
Conditions: Seizures, Lennox Gastaut Syndrome
Register for Updates
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
NCT05548296
Recruiting
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Texas Oncology-Dallas Presbyterian Hospital, Dallas, Texas +1 locations
Conditions: Endometrial Adenocarcinoma
Register for Updates
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237
Recruiting
The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Texas Oncology, Dallas, Texas
Conditions: Non-small Cell Lung Cancer
Register for Updates
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
NCT04301843
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.
Gender:
ALL
Ages:
31 years and below
Trial Updated:
07/21/2025
Locations: Children's Medical Center Dallas, Dallas, Texas
Conditions: Neuroblastoma
Register for Updates
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764
Recruiting
The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin (BCG) therapy and who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Urology Clinics of North Texas, Dallas, Texas +1 locations
Conditions: Non-Muscle Invasive Bladder Neoplasms
Register for Updates
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
NCT06620003
Recruiting
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/21/2025
Locations: Synexus Clinical Research US; Inc., Dallas, Texas
Conditions: Marburg Virus Disease
Register for Updates
Study of ALTO-300 in MDD
NCT05922878
Recruiting
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/21/2025
Locations: Site 102, Dallas, Texas
Conditions: Major Depressive Disorder
Register for Updates
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
NCT06581432
Recruiting
This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of this study is to find out whether a medicine called zongertinib helps people with advanced cancers with HER2 alterations. HER2 alterations can cause cancer. Zongertinib inhibits HER2. Participants are put into 13 groups based on the type of advanced cancer and the type of HER2 alterations they have.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Mary Crowley Cancer Research Center, Dallas, Texas
Conditions: Solid Tumours
Register for Updates
A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
NCT06381141
Recruiting
A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (anti-MICA/MICB Antibody) in Patients with Relapsed and Refractory Multiple Myeloma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Multiple Myeloma
Register for Updates
Exploring Neurophysiological Markers of Brain Health
NCT06731452
Recruiting
The combination of transcranial magnetic stimulation (TMS) and electroencephalography (EEG) has been suggested as a promising brain imaging tool for identifying biomarkers of brain health. In this pilot study, study investigators will explore the neurophysiological metrics of brain health with a non-invasive brain imaging technique, alongside behavioral and fMRI metrics collected through another study (NCT04869111).
Gender:
ALL
Ages:
Between 22 years and 100 years
Trial Updated:
07/21/2025
Locations: Center for BrainHealth at The University of Texas at Dallas, Dallas, Texas
Conditions: Healthy Lifestyle, Health-Related Behavior
Register for Updates
Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
NCT06924021
Recruiting
1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/21/2025
Locations: Retina Foundation of the Southwest, Dallas, Texas
Conditions: Age-Related Macular Degeneration
Register for Updates